Physician profile
Scott Kreisel Roos
NPI 1770596983
$5,763.83
in general payments reported to CMS, 2019-2025
49 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,712 · 2020: $383 · 2021: $498 · 2022: $826 · 2023: $1,085 · 2024: $995 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.79 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $666.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $536.63 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $457.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $408.14 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $229.73 | 2019-2022 | |
| Lilly USA, LLC | $225.85 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Astellas Pharma US INC | $223.54 | 2019-2021 | |
| Amgen INC. | $164.69 | 2019-2024 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.57 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $142.72 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $131.21 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $127.28 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $124.73 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $112.92 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Roos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.